Boston Scientific Acquires Valencia Technologies to Enhance Urology Solutions and Address Bladder Dysfunction
- Boston Scientific acquires Valencia Technologies to enhance its urology portfolio and address overactive bladder solutions.
- The acquisition includes Valencia's FDA-approved eCoin® System, improving treatment options for urge urinary incontinence.
- Boston Scientific aims to expand its pelvic health product line and improve patient care through innovative technologies.
Boston Scientific Strengthens Urology Portfolio with Valencia Technologies Acquisition
Boston Scientific Corporation takes a significant step towards enhancing its urology offerings by entering into a definitive agreement to acquire Valencia Technologies Corporation, a medical technology firm specializing in bladder dysfunction solutions. This acquisition, announced on January 12, 2026, is particularly relevant as it targets the growing issue of overactive bladder (OAB), a condition that affects nearly 30 million adults aged 40 and older in the United States. By integrating Valencia's innovative technologies, Boston Scientific aims to bolster its position in a market that is increasingly focused on patient-centered care and advanced therapeutic options.
Valencia Technologies brings to Boston Scientific its FDA-approved eCoin® System, an implantable tibial nerve stimulation (ITNS) device designed to treat urge urinary incontinence (UUI), one of the most common symptoms associated with OAB. The eCoin device, which is approximately the size of a coin, is implanted under the skin near the ankle, providing a less invasive alternative for patients who have not found relief through traditional treatments. Preliminary clinical trials indicate that 68% of participants experience at least a 50% reduction in UUI episodes post-implantation, underscoring the device's potential efficacy and the demand for innovative solutions in this therapeutic area.
Meghan Scanlon, senior vice president and president of Urology at Boston Scientific, emphasizes that this acquisition will significantly expand the company’s ITNS capabilities and enhance its existing pelvic health product line. By offering a more comprehensive range of treatment options, Boston Scientific positions itself to better meet the needs of patients suffering from bladder dysfunction, ultimately aiming to improve their quality of life. The transaction is set to finalize in the first half of 2026, subject to customary closing conditions, and while it may have a minor impact on the company’s adjusted earnings per share, it is expected to incur greater dilution on a GAAP basis due to acquisition costs.
In addition to its focus on innovation, Boston Scientific has a rich history of leading advancements in medical technology for over 45 years. The company's commitment to improving patient health and reducing healthcare costs is evident in its strategic acquisitions and development of cutting-edge medical devices. The addition of Valencia Technologies further solidifies Boston Scientific's role as a key player in the urology sector, reinforcing its dedication to delivering effective solutions for patients with complex health challenges.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

